Antimicrobial resistance (AMR) is now recognized as a global threat to human health. The accessibility of microbial whole-genome sequencing offers an invaluable opportunity for resistance surveillance via the resistome, i.e. the genes and mutations underlying AMR. Unfortunately, AMR prediction from genomic data remains extremely challenging, especially for species with a large pan-genome. One such organism, for which multidrug-resistant (MDR) isolates are frequently encountered in the clinic, is Pseudomonas aeruginosa. This study focuses on a commercially available panel of seven MDR P. aeruginosa strains. The main goals were to sequence and compare these strains' genomes, attempt to predict AMR from whole genomes using two different methods and determine whether this panel could be an informative complement to the international P. aeruginosa reference panel. As expected, the results highlight the complexity of associating genotype and AMR phenotype in P. aeruginosa, mainly due to the intricate regulation of resistance mechanisms. Our results also urge caution in the interpretation of predicted resistomes regarding the occurrence of gene identity discrepancies between strains. We envision that, in addition to accounting for the genomic diversity of P. aeruginosa, future development of predictive tools will need to incorporate a transcriptomic, proteomic and/or metabolomic component.
INTRODUCTION
The emergence of antimicrobial resistance (AMR) is now recognized as a global threat to human health (World Health Organization 2015) . In fact, it is widely accepted that we have entered the post-antibiotic era, due to the increasing occurrence of multidrug-resistant (MDR) pathogens and the failure to compensate this phenomenon with drug discovery (Brown and Wright 2016) . In order to guide worldwide epidemiological surveillance, drug-resistant bacteria have been categorized as MDR, extensively drug-resistant (XDR) and pandrug-resistant (PDR) (Magiorakos et al. 2012) . MDR is defined as resistance to at least one antibiotic in three different antimicrobial categories, XDR corresponds to resistance to at least one antibiotic in all but one or two antimicrobial categories and PDR means resistance to all available antibiotics. Next-generation sequencing technologies combined with the impressive number of sequenced bacterial genomes to date (Land et al. 2015) represent an invaluable source of information for such surveillance via the resistome, i.e. the genes and mutations underlying AMR. Still, despite the numerous bioinformatics tools that have already been developed, AMR prediction from genomic data remains extremely challenging (McArthur and Tsang 2016; Jeukens et al. 2017) . Recent tools have shown remarkable success in AMR phenotype prediction for select organisms, namely Mycobacterium tuberculosis and Staphylococcus aureus (Bradley et al. 2015; Davis et al. 2015) . However, a study on Streptococcus pneumoniae revealed not only the complexity of bacteria's response to antibiotics, but also the variability of this response among strains, arguing that this may be especially true for species with a large pan-genome (van Opijnen, Dedrick and Bento 2016) .
One of the organisms for which MDR and XDR isolates are frequently encountered in the clinic is Pseudomonas aeruginosa (Oliver et al. 2015) , an environmental gram-negative bacterium and opportunistic pathogen (Lyczak, Cannon and Pier 2000) . The need for better understanding of P. aeruginosa, namely in terms of AMR evolution, motivated the creation of an international consortium of researchers whose combined efforts crystallized into the International Pseudomonas Consortium Database (IPCD, https://ipcd.ibis.ulaval.ca/). This database is the repository for details of a highly diverse strain collection and data of a genome sequencing initiative (Freschi et al. 2015) .
This study focuses on a commercially available panel of seven MDR P. aeruginosa strains that we fully sequenced and included in the IPCD. Our original goals were to describe and compare these strains' genomes before attempting to associate their resistomes with empirical measures of antibiotic resistance using two different approaches. Considering that P. aeruginosa has a large and complex pan-genome (Klockgether et al. 2011; Mosquera-Rendón et al. 2016) , and based on the results of previous studies (Kos et al. 2015; Drouin et al. 2016a) , we expected genotype-phenotype associations to be difficult to establish for most AMR phenotypes. We also sought to evaluate whether this panel could be an informative complement to the international P. aeruginosa reference panel (De Soyza et al. 2013; Cullen et al. 2015) , based on both AMR genotype and phenotype.
MATERIALS AND METHODS

Pseudomonas aeruginosa drug-resistant strains
The Drug-resistant Pseudomonas aeruginosa Panel (ATCC R MP-23, Cedarlane, Burlington, ON, Canada), composed of seven strains, was included in the IPCD (https://ipcd.ibis.ulaval.ca/) strain collection. These strains were all isolated from cystic fibrosis patients (Ramsey et al. 1993) and exhibit resistance against up to 20 antibiotics. AMR phenotypes for the production lots sequenced in this study are compiled in Table 1 . According to the definitions provided by Magiorakos et al. (2012) , some phenotypes are missing for a formal classification, but based on available data, all seven strains are at least MDR.
DNA library preparation and genome sequencing
Bacterial colonies were isolated on DifcoTM Pseudomonas Isolation Agar (BD, Sparks, MD, USA). Genomic DNA was extracted from overnight liquid cultures (37
• C, LB medium) using the E-Z 96 Tissue DNA Kit (Omega Bio-tek, Norcross, GA, USA). (Tritt et al. 2012) .
Core genome phylogeny
To have a general idea of the genetic diversity and relatedness of the seven ATCC strains, we performed phylogenetic analysis of the core genome using the Harvest suite version v1.1.2 (Treangen et al. 2014) . In addition to the ATCC panel, we included a set of 53 genomes that was previously described as genetically diverse (Stewart et al. 2014) , while excluding group 3 genomes (PA7-like).
Resistome analysis
AMR genes were identified in each genome based on the Comprehensive Antibiotic Resistance Database (CARD) v.1.1.4 (McArthur et al. 2013) . This was done using the command-line version of the Resistance Gene Identifier (RGI) software, version 3.1.1 (McArthur et al. 2013) . This software performs blastp searches against the CARD and uses curated e-value cut-offs to determine the presence of genes or variants associated with AMR.
Prediction of resistance based on machine learning
Machine learning typically requires a large dataset of both genotypes and phenotypes, which was not available here. However, Kover, an implementation of the Set Covering Machine (Drouin et al. 2016a) , was recently used to generate predictive models of antibiotic resistance with data from the PATRIC database (Wattam et al. 2014; Drouin et al. 2016b ). These models are available through the Kover AMR Platform (https:// aldro61.github.io/kover-amr-platform/index.html), and include four models for P. aeruginosa. They were applied to the genomes described here in an attempt to predict resistance to amikacin (aminoglycoside), meropenem (beta-lactam), levofloxacin (quinolone) and ciprofloxacin (quinolone).
RESULTS AND DISCUSSION
Genome sequencing and assembly
Genomes of the ATCC drug-resistant panel strains were sequenced and assembled to IPCD standards, with 23 to 62 scaffolds per genome (Table 2) . Assemblies have been deposited at DDBJ/ENA/GenBank under the accession numbers provided in Table 2 , as part of BioProject PRJNA325248 ('International Pseudomonas aeruginosa Consortium genome sequencing project'). 
Modified from https://www.atcc.org/Products/All/MP-23.aspx#generalinformation to include antibiotic resistance phenotypes for the specific lots that were sequenced in this study. All of them were tested with the bioMérieux VITEK 2 parameter set CLSI + Natural Resistance, MIC Guideline CLSI M100-S22 (2012). The VITEK 2 AST-GN69 and VITEK 2 AST-XN06 cards were used for BAA-2108, BAA-2109, BAA-2111 and BAA-2112; the VITEK 2 AST-GN69 card was used for BAA-2110, BAA-2113 and BAA-2114. a De novo genome assembly and corresponding statistics were obtained using the A5 pipeline version A5-miseq 20140521 (Tritt et al. 2012) . 
Assessment of genomic diversity
Since all seven strains presented here came from the same study on American cystic fibrosis patients, the first analysis in this study aimed to determine the extent of genomic diversity represented by these seven strains. The core genome phylogeny that was produced, which included a set of known genetically diverse strains (Stewart et al. 2014) , confirmed that they were all distinct strains, and reasonably well spread across group 1 (Fig. 1) . This so-called group 1 is the most common phylogenetic cluster in P. aeruginosa, at least among clinical isolates (Freschi et al. 2015) .
Resistome analysis
Identifying the genetic basis of a trait de novo requires a large dataset of both genotypes and phenotypes (Bradley et al. 2015; Drouin et al. 2016a) . With the small number of strains available here, we had to rely on a database approach to identify the potential genetic determinants of AMR. The CARD was chosen because it is one of the most comprehensive and up-to-date resource of its kind. The literature suggests that the only comparable database is ARG-ANNOT (Gupta et al. 2014; Jia et al. 2017 ), although we argue that it has limitations. First, it is not clear whether the ARG database is updated as often as was originally claimed by the authors (Gupta et al. 2014) . The website neither indicates the version nor the date of its current downloadable version, while this information is perfectly transparent on the CARD website. Second, the tool ARG-ANNOT was meant to be used with software BioEdit, while there is a commandline version of RGI that can be easily parallelized. Hence, RGI based on the CARD is a much more viable option for large datasets. Figure 2 shows the resistomes of the drug-resistant panel strains plus three reference strains: PAO1, LESB58 and PA14. The seven drug-resistant strains, which exhibit phenotypic variability in their response to 27% of the antibiotics tested (Table 1) , also show diversity in their resistomes. However, they do not carry exceptionally rare resistance genes. In fact, all genes and variants represented in Fig. 2 are present in at least one of the three reference strains. Hierarchical clustering based on resistome composition revealed that the drug-resistant panel strains are clearly distinct from PAO1, a relatively sensitive strain (Cullen et al. 2015) . The resistome of BAA-2114 was similar to that of LESB58, a MDR strain.
Linking genotype to AMR phenotype using a database approach
Predicting resistance from the resistome is generally not straightforward. By using RGI, we are investigating the presence of certain genes, proteins or specific variants. Yet, the presence of such features does not inform us on whether they are expressed or functional. Moreover, many resistance phenotypes, namely those implicating efflux systems, are influenced by multiple genes whose expression varies according to environmental conditions and complex regulatory networks (Li and Plésiat 2016) . Here, taking advantage of the limited number of strains in this study, we focused on divergent phenotypes (Table 1) , and attempted to associate each one with divergent features in Fig. 2 . This approach is obviously not realistically applicable to large datasets.
Strain BAA-2114, like strain LESB58 (Cullen et al. 2015) , was resistant to piperacillin/tazobactam (beta-lactam). Both are distinguishable by their variant of Pseudomonas-derived cephalosporinase (PDC-3), generally referred to as AmpC β-lactamase. This variant was shown to have increased enzymatic activity (Rodríguez-Martínez, Poirel and Nordmann 2009a), but it is not systematically associated with resistance to piperacillin/tazobactam. Some PDC variants have been associated with reduced susceptibility to ceftazidime (Rodríguez-Martínez, Poirel and Nordmann 2009a), but it was not the case for PDC-6. Hence, this variant cannot account for the intermediate resistance of strain BAA-2113 to ceftazidime. Overexpression level of intrinsic gene ampC plays an important role in resistance to beta-lactams (Cabot et al. 2011) , and may be responsible for these phenotypes.
Strain BAA-2108, the only strain of the panel that is resistant to imipenem, is distinguishable in Fig. 2 by the lack of mexS, mexE and oprN. Imipenem resistance is generally associated with efflux pump overexpression, or mutation/loss/repression of porin OprD (Rodríguez-Martínez, Poirel and Nordmann 2009b). Mutation or loss of mexS, which represses activator mexT (not included in CARD) of pump MexEF-OprN, was associated with multidrug resistance (Sobel, Neshat and Poole 2005) . Overexpression of mexT also suppresses porin OprD, causing imipenem resistance (Ochs et al. 1999) . Since regulators mexS and mexT are both missing in BAA-2108, they cannot be responsible for OprD repression, and we manually verified that OprD in BAA-2108 is not mutated, as this protein is not included in CARD. Regulation of OprD is known to be controlled by a plethora of compounds and regulators; although it is not accounted for in Fig. 2 , its repression is the most likely mechanism of resistance at play in BAA-2108 (Perron et al. 2004; Li et al. 2012) . Strain BAA-2108 is also characterized by resistance to aminoglycosides (Table 1) , like strain LESB58 (Fig. 2) , which is resistant to amikacin and gentamicin (Cullen et al. 2015) . Again, this is likely due to the involvement and regulation of efflux mechanisms (Poole 2005 ; Garneau-Tsodikova and Labby 2016), which are not accounted for in Fig. 2 .
Resistance to quinolones is typically the easiest to predict, as it is largely influenced by a single gene encoding DNA gyrase (Yonezawa et al. 1995) . Here, LESB58 and BAA-2114 share the same gyrA variant, and are both resistant to ciprofloxacin as well as levofloxacin, although resistance is intermediate for strain BAA-2114 . Results for resistance to moxifloxacin, however, are quite different. Resistance to this fourth-generation fluoroquinolone is emerging and therefore less well described (Oldenburg et al. 2013) . Moreover, efflux pumps also have an impact on quinolone resistance in P. aeruginosa (Jalal et al. 2000; Lomovskaya et al. 2001; Kriengkauykiat et al. 2005) , which likely complicates the interpretation of these phenotypes.
To further complicate the comparison of resistomes among multiple genomes, we have discovered gene identity discrepancies between strains for a subset of genes. We remain confident that the majority of RGI results are sound, but we would like to urge caution in the interpretation of the results for six genes. This analysis emerged from the observation that the CARD nomenclature does not always correspond to commonly used gene names in P. aeruginosa. Therefore, for strains PAO1 and LESB58, which are well annotated, we associated each RGI result with the locus tag and annotation available on the Pseudomonas genome database (pseudomonas.com; Winsor et al. 2015) . The full results for 63 genes are presented in Table 1 , Supporting Information; the 13 genes for which discrepancies were identified between CARD and pseudomonas.com are shown in Table 3 . Differences in gene names for seven genes are not a real concern for result interpretation, though being aware of them may be relevant. However, the fact that a single name in CARD can represent multiple loci is worrisome, especially if this varies among genomes. This was the case for six efflux-related genes in our dataset. The best example is CARD's mexF, which corresponds to 2 loci in PAO1, and 4 in LESB58. This example casts doubt on whether we are really looking at the same locus when comparing genetically diverse isolates of Pseudomonas, at least for the six multicopy genes listed in Table 3 . It also raises questions on the extent of functional redundancy of these genes. Considering that CARD is updated monthly and that the developers are specifically addressing the case of efflux genes, we expect the identification of these genes to become more reliable. We also expect that mexT and OprD, which we have reported to be missing from CARD, will ultimately be included.
Linking genotype to AMR phenotype using machine learning
Predictive models developed by machine learning are a promising approach to overcome the major disadvantage of relying on a database, i.e. the complete dependence on known mechanisms of resistance. Moreover, they can easily predict phenotypes for large genomic datasets. To date, however, machine learning applied to P. aeruginosa AMR has had mitigated success (Drouin et al. 2016a,b) , due to the genomic complexity of the species. Here, we applied predictive models for resistance to amikacin (11% average error rate in discriminating resistant and sensitive isolates from 10 repeats of 99 isolate test sets), levofloxacin (6% error rate), ciprofloxacin (4% error rate) and meropenem (28% error rate). The levofloxacin, ciprofloxacin and meropenem models are all based upon a fragment, or kmer, of gyrA. All drug-resistant panel strains were predicted to be susceptible to meropenem, which is accurate based on the partial phenotypic data in Table 1 . Resistance to levofloxacin, but not to ciprofloxacin, was predicted for BAA-2114. In fact, it has intermediate resistance to both antibiotics according to ATCC information, but Kover was not designed to predict such phenotypes. Finally, the amikacin model, which relies on the presence/absence of 5 k-mers, failed to predict resistance for BAA-2108, while correctly predicting sensitivity for all other strains. These models were optimized to have the least number of rules, i.e. to rely on the least number of k-mers. Knowing the complexity of mechanisms underlying AMR in P. aeruginosa, a strategy targeting more complex models should be envisioned. Strains PAO1 and LESB58 annotations were retrieved from the Pseudomonas genome database (pseudomonas.com).
Relevance of the drug-resistant panel given the international Pseudomonas aeruginosa reference panel
Considering global genetic diversity, resistome, AMR phenotypes as well as bacterial strain and sequence data availability (Cullen et al. 2015; C. Winstanley, personal communication) , the drug-resistant panel described here does not add anything significant to the international P. aeruginosa reference panel. It represents an alternative for those interested in performing further experimentation using MDR strains, though it is important to keep in mind that there are more resistant strains out there, namely high-risk MDR/XDR clones and PDR strains (Oliver et al. 2015; Xiong et al. 2017) . In fact, the breadth of resistome diversity in this species suggests that a more extensive panel of strains will be a pre-requisite for the study of AMR and AMR prediction (Freschi et al. 2015) .
As if hurdles in the field of drug discovery were not enough, this study contributes to the demonstration that understanding and predicting AMR in a diverse and complex microbe such as P. aeruginosa is extremely challenging. It also highlights worrisome AMR gene identity discrepancies among strains of this species. Much works remain to develop reliable predictive tools. Efflux regulation plays such a key role in this organism that we can anticipate the need for these future tools to incorporate a transcriptomic, proteomic and/or metabolomic component.
